Q3 EPS Estimate for Johnson & Johnson Raised by Analyst

Key Points

• Zacks Research has raised its Q3 2025 earnings per share estimate for Johnson & Johnson to $2.79, up from $2.73, reflecting a positive outlook for the company.
• The current consensus estimate for Johnson & Johnson's full-year earnings stands at $10.58 per share, with projected earnings for FY2026 estimated at $11.22 per share.
• Johnson & Johnson's stock received multiple rating upgrades, with Goldman Sachs raising its price target from $157.00 to $172.00 and a majority of analysts rating it as a buy or strong buy.

Johnson & Johnson (NYSE:JNJ - Free Report) - Investment analysts at Zacks Research lifted their Q3 2025 earnings per share estimates for Johnson & Johnson in a research report issued to clients and investors on Tuesday, July 29th. Zacks Research analyst K. Shah now forecasts that the company will post earnings of $2.79 per share for the quarter, up from their previous forecast of $2.73. The consensus estimate for Johnson & Johnson's current full-year earnings is $10.58 per share. Zacks Research also issued estimates for Johnson & Johnson's Q4 2025 earnings at $2.51 EPS, Q2 2026 earnings at $2.85 EPS, Q3 2026 earnings at $2.88 EPS, Q4 2026 earnings at $2.85 EPS and FY2026 earnings at $11.22 EPS.

Several other equities analysts have also recently weighed in on JNJ. Guggenheim reiterated a "neutral" rating and issued a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Finally, Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Nine analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $174.50.

Johnson & Johnson Stock Performance

Shares of JNJ traded up $2.59 during mid-day trading on Thursday, hitting $167.33. The stock had a trading volume of 8,914,735 shares, compared to its average volume of 8,384,981. The firm has a market cap of $402.99 billion, a P/E ratio of 17.90, a PEG ratio of 2.10 and a beta of 0.41. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The business has a fifty day moving average price of $157.46 and a 200-day moving average price of $156.60.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The business's revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the company posted $2.82 earnings per share.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.1%. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Brighton Jones LLC raised its position in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Hudson Value Partners LLC raised its position in shares of Johnson & Johnson by 2.5% in the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after acquiring an additional 1,022 shares in the last quarter. Potomac Fund Management Inc. ADV bought a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $625,000. Meeder Advisory Services Inc. raised its position in shares of Johnson & Johnson by 2.4% in the 4th quarter. Meeder Advisory Services Inc. now owns 37,359 shares of the company's stock worth $5,403,000 after acquiring an additional 882 shares in the last quarter. Finally, RFG Bristol Wealth Advisors LLC bought a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $928,000. Institutional investors own 69.55% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.